USRE34580E - Process for the preparation of a stable modification of torasemide - Google Patents

Process for the preparation of a stable modification of torasemide Download PDF

Info

Publication number
USRE34580E
USRE34580E US07/985,053 US98505392A USRE34580E US RE34580 E USRE34580 E US RE34580E US 98505392 A US98505392 A US 98505392A US RE34580 E USRE34580 E US RE34580E
Authority
US
United States
Prior art keywords
torasemide
modification
iaddend
iadd
rearrangement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/985,053
Inventor
Fritz Topfmeier
Gustav Lettenbauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda AB
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Priority to US07/985,053 priority Critical patent/USRE34580E/en
Application granted granted Critical
Publication of USRE34580E publication Critical patent/USRE34580E/en
Assigned to ROCHE DIAGNOSTICS GMBH reassignment ROCHE DIAGNOSTICS GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BOEHRINGER MANNHEIM GMBH
Anticipated expiration legal-status Critical
Assigned to MEDA AB reassignment MEDA AB CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ROCHE DIAGNOSTICS GMBH
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Definitions

  • the present invention is concerned with a process for the preparation of a stable modification of torasemide.
  • Torasemide (1-isopropyl-3-[(4-m-toluidino-3-pyridyl)-sulphonyl]-urea) is a compound with interesting pharmacological properties which is described in Example 71 of Federal Republic of Germany Patent Specification No. 25 16 025.
  • this compound has a strong diuretic action in the case of which water and sodium ions are excreted relatively more strongly than potassium ions.
  • the compound is, therefore, of great interest as a diuretic agent.
  • modification I crystallises monoclinically in the space group P2 1 /c
  • modification II crystallises monoclinically in the space group P2/n.
  • modification II which usually also results in the case of recrystallisations from other solvents. Since this form, in the case of storage of the pure active material, does not change and, in the case of all purification experiments, forms the predominant form, it was assumed that this modification II is also stable. Surprisingly, we have now ascertained that torasemide of modification II, when it is present in very finely divided form in pharmaceutical tablets, rearranges more or less quickly into modification I, whereby the crystal size and speed of dissolving of the active material upon introducing the tablets into water can be significantly changed.
  • the present invention provides oral forms of administration which contain torasemide of modification I as active material.
  • Oral forms of administration containing torasemide of modification I are produced in the usual way with the use of pharmacologically acceptable adjuvants, for example sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould separation agents and anti-adhesion agents, as well as possible flow regulation agents.
  • pharmacologically acceptable adjuvants for example sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould separation agents and anti-adhesion agents, as well as possible flow regulation agents.
  • aqueous process steps for example granulation, can be carried out.
  • the formulations according to the present invention have a rapid in vitro rate of dissolving which remains unchanged even after comparatively long storage at temperatures higher than ambient temperature and at a comparatively high atmospheric humidity.
  • compositions The rapidly commencing pharmacological action of these compositions is ensured by the rapid rate of dissolving of the active material from the form of administration.
  • the test method used being the paddle test USP XXI.
  • Torasemide which has been prepared according to Federal Republic of Germany Patent Specificatio No. 25 16 025 and has been purified by reprecipitation from sodium bicarbonate solution with carbon dioxide, are suspended in the 10 fold amount og water and 100 g. of torasemide of modification I from a previous batch are added thereto. The suspension is heated to 90° C., stirred at this temperature for 6 hours, cooled to ambient temperature and again stirred for 30 minutes. Thereafter, the crystalls are filtered off with suction, washed with 40 liters of water and dried in a vacuum drying cabinet at 50° C., 9.91 kg. of torasemide of modification I being obtained.
  • the X-ray diffraction diagram corresponds to that of the pure modification I and a testing for purity with HPLC corresponds to the pure starting material.
  • Crystal nuclei of modification I can possibly also be obtained according to the process described in Acta Cryst., 1978, p. 1304.
  • Torasemide of modification II are suspended in 10 liters of water and stirred at ambient temperature in the presence of 10 g. torasemide of modification I. After 8 days, a sample no longer contains any trace of modification II. The product is filtered off and dried in a vacuum drying cabinet at 50° C., 875 g. of torasemide of modification I thereby being obtained.
  • the purity corresponds to that of the starting material and the X-ray crystallographic spectrum corresponds to that of the pure modification I.
  • the suspension is cooled to ambient temperature and the crystallisate is centrifuged off.
  • the crystallisate is washed with 50 liters of water and finally dried at 50° C. in a vacuum drying cabinet, 9.82 g. of pure torasemide of modification I being obtained.
  • This Example shows that the rearrangement according to the present invention can also be carried out in the presence of foreign salts such as are present in the case of the normal precipitation of torasemide.
  • Torasemide of modification I is mixed in the usual way with lactose monohydrate and maize starch, granulated with water, dried and sieved (granulate 1). Highly dispersed silicon dioxide and magnesium stearate are mixed, sieved and admixed with granulate 1. This mixture is then tabletted in conventional manner.
  • silicon dioxide highly dispersed: 60.00 g.
  • magnesium stearate 40.00 g.
  • Torasemide of modificatio I is mixed with lactose monohydrate, maize starch and a part of the magnesium stearate.
  • the mixture is compacted and sieved to the desired gain size and grain size distribution (granulate 1).
  • Highly dispersed silicon dioxide and magnesium stearate are mixed and sieved and admixed with granulate 1.
  • the mixture is then tableted in conventional manner:
  • lactose monohydrate 2.0 kg.
  • silicon dioxide highly dispersed: 0.2 kg.
  • magnesium stearate 0.1 kg.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides a process for the preparation of crystalline torasemide in the pure modification I (monoclinic, space group P21 /c, .[.melting point 162° C.).]. .Iadd.in prism form) .Iaddend.from torasemide of modification II (monoclinic, space group P2/n, .[.melting point 169°.),.]. .Iadd.in leaflet form), .Iaddend.wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete.
The present invention also provides a pharmaceutical compositions containing .Iadd.stable .Iaddend.torasemide of modification I.

Description

The present invention is concerned with a process for the preparation of a stable modification of torasemide.
Torasemide (1-isopropyl-3-[(4-m-toluidino-3-pyridyl)-sulphonyl]-urea) is a compound with interesting pharmacological properties which is described in Example 71 of Federal Republic of Germany Patent Specification No. 25 16 025. In particular, this compound has a strong diuretic action in the case of which water and sodium ions are excreted relatively more strongly than potassium ions. The compound is, therefore, of great interest as a diuretic agent.
In the preparation of this compound, a purification is normally included in which the compound in question is dissolved in an aqueous or aqueous alcoholic solution of sodium hydrogen carbonate and, after filtering off from impurities, the torasemide is again precipitated out with acetic acid or carbon dioxide. In the case of this process, the product is obtained in the form of white crystals with a melting point of 163°-164° C.
From Acta Cryst., 1978, pp. 2659-2662 and Acta Cryst., 1978, pp. 1304-1310, it is known that torasemide can occur in two modifications which differ X-ray crystallographically. Both modifications are simultaneously present when a solution of torasemide in petroleum ether/ethanol is slowly evaporated. The crystals, which are characterised not only as prisms .[.with a melting point of 169° C..]. but also as leaflets .[.with a melting point of 162° C.,.]. are, however, only described in these literature references with regard to their X-ray crystallographic properties. The modifications .[.with the melting point of 169° C..]., which is hereinafter referred to as modification I, crystallises monoclinically in the space group P21 /c, and the modification .[.with the melting point of 162° C.,.]. which is hereinafter referred to as modification II, crystallises monoclinically in the space group P2/n.
The modification obtained in the case of the preparation and normal purification by precipitating the torasemide with carbon dioxide is modification II which usually also results in the case of recrystallisations from other solvents. Since this form, in the case of storage of the pure active material, does not change and, in the case of all purification experiments, forms the predominant form, it was assumed that this modification II is also stable. Surprisingly, we have now ascertained that torasemide of modification II, when it is present in very finely divided form in pharmaceutical tablets, rearranges more or less quickly into modification I, whereby the crystal size and speed of dissolving of the active material upon introducing the tablets into water can be significantly changed. Since, on the other hand, as is known, the speed of dissolving represents one of the important characteristics of a pharmaceutical form of administration and thus, in order to be able to dose reproducibly, must not differ from one tablet to another, the problem exists of finding a form of administration of torasemide which does not change its speed of dissolving during storage. Since the uncontrollable change of the speed of dissolving depends upon the rearrangement of modification II into modification I of the torasemide, it was obvious ab initio to use modification I from which, from our investigations, it followed that it is also stable in tablets and did not rearrange again back into modification II.
Therefore, the present invention provides oral forms of administration which contain torasemide of modification I as active material.
The process, which is sufficient for X-ray crystallography, of allowing both modifications to crystallise out together from the same solvent mixture and to separate them according to their macroscopic crystal form is, of course, useless for a large-scale preparation since such a separation of the crystals would not be feasible. Furthermore, it was known that torasemide, upon heating in most solvents, cyclises irreversible with the anilino nitrogen atom. Therefore, a recrystallisation from most solvents is not suitable for the preparation of modification I. Consequently, there was the further problem of finding a process for the preparation of the pure modification I of torasemide which can be carried out simply and economically and without decomposition of the torasemide.
Surprisingly, we have now found that torasemide of modification II can be rearranged into modification I when a suspension thereof in water is seeded with very finely divided crystal nuclei of modification I and this suspension is stirred until the whole amount thereof has undergone rearrangement into modification I.
At ambient temperature, this rearrangement takes place relatively slowly so that a period of 10 to 14 days is necessary. However, the suspension can also be heated to temperatures of 70° to 90° C., in which case the reaction proceeds to completion within 3 to 6 hours. Whereas in the case of heating torasemide in solvents such as ethanol, ehtyl acetate, methylene chloride and chloroform, decomposition products are formed in considerable amounts, torasemide can, surprisingly, be heated in water for several days to 90° C. without noticeable decomposition. Furthermore, it was surprising that even the addition of small amounts (up to 1%) bring about a rearrangement since torasemide of modification I has, in any case, a solubility of 1.9 g./liter at 90° C. Purely on the basis of the solubility, it was to have been expected that these small amounts of torasemide would dissolve in the aqueous suspension medium.
Since the rearrangement itself proceeds even in pure water, this process has the further advantage that no additional impurities, such as solvents, catalytically-acting acids or bases, etc. are entrained into the product. On the contrary, due to the recrystallisation procedure, impurities present in the original modification II pass into the water.
Oral forms of administration containing torasemide of modification I are produced in the usual way with the use of pharmacologically acceptable adjuvants, for example sugar, starch, starch derivatives, cellulose, cellulose derivatives, mould separation agents and anti-adhesion agents, as well as possible flow regulation agents. In particular, in the case of the use of torasemide of modification I, aqueous process steps, for example granulation, can be carried out.
For the aimed for quality-determining parameter of the form of administration according to the present invention, it is especially advantageous when the active material torasemide of modification I is used with the following particle size distribution:
at least 90%≦96 μm. and
at least 50%≦48 μm.
In comparison with pharmaceutical formulations with the active material torasemide of modification II, the formulations according to the present invention have a rapid in vitro rate of dissolving which remains unchanged even after comparatively long storage at temperatures higher than ambient temperature and at a comparatively high atmospheric humidity.
The rapidly commencing pharmacological action of these compositions is ensured by the rapid rate of dissolving of the active material from the form of administration. Thus, for example, after 15 minutes more than 60% has gone into solution and after 30 minutes more that 80%, the test method used being the paddle test USP XXI.
The following Examples are given for the purpose of illustrating the present invention:
EXAMPLE 1
10 kg. Torasemide, which has been prepared according to Federal Republic of Germany Patent Specificatio No. 25 16 025 and has been purified by reprecipitation from sodium bicarbonate solution with carbon dioxide, are suspended in the 10 fold amount og water and 100 g. of torasemide of modification I from a previous batch are added thereto. The suspension is heated to 90° C., stirred at this temperature for 6 hours, cooled to ambient temperature and again stirred for 30 minutes. Thereafter, the crystalls are filtered off with suction, washed with 40 liters of water and dried in a vacuum drying cabinet at 50° C., 9.91 kg. of torasemide of modification I being obtained.
The X-ray diffraction diagram corresponds to that of the pure modification I and a testing for purity with HPLC corresponds to the pure starting material.
Crystal nuclei of modification I can possibly also be obtained according to the process described in Acta Cryst., 1978, p. 1304.
EXAMPLE 2
900 g. Torasemide of modification II are suspended in 10 liters of water and stirred at ambient temperature in the presence of 10 g. torasemide of modification I. After 8 days, a sample no longer contains any trace of modification II. The product is filtered off and dried in a vacuum drying cabinet at 50° C., 875 g. of torasemide of modification I thereby being obtained. The purity corresponds to that of the starting material and the X-ray crystallographic spectrum corresponds to that of the pure modification I.
For comparison, the same batch but without the addition of modification I was stirred at ambient temperature for 10 days without a rearrangement into modification I taking place.
EXAMPLE 3
10 kg. Crude torasemide, which had been prepared according to the procedure of Federal Republic of Germany Patent Specification No. 25 16 025, is suspended in 100 liters of water and mixed with 30 liters of 1N aqueous sodium hydroxide solution. After treatment with 500 g. of active charcoal and filtration, there is obtained a clear yellowish solution from which, by the addition of 1N sulphuric acid at ambient temperature up to the achievement of a pH value of 7.5, the torasemide is again precipitated out (consumption about 29 liters). 100 g. of torasemide of modification I are added to this suspension and the solution is heated for 6 hours to 90° C. During this time, the modification rearrangement takes place. The suspension is cooled to ambient temperature and the crystallisate is centrifuged off. The crystallisate is washed with 50 liters of water and finally dried at 50° C. in a vacuum drying cabinet, 9.82 g. of pure torasemide of modification I being obtained.
This Example shows that the rearrangement according to the present invention can also be carried out in the presence of foreign salts such as are present in the case of the normal precipitation of torasemide.
EXAMPLE 4 Production of a 2.5 mg. tablet
Torasemide of modification I is mixed in the usual way with lactose monohydrate and maize starch, granulated with water, dried and sieved (granulate 1). Highly dispersed silicon dioxide and magnesium stearate are mixed, sieved and admixed with granulate 1. This mixture is then tabletted in conventional manner.
Production formulation for 100,000 tablets:
torasemide: 0.25 kg.
lactose monohydrate: 6.05 kg.
maize starch: 1.60 kg.
silicon dioxide, highly dispersed: 60.00 g.
magnesium stearate: 40.00 g.
water, purified: 1.20 kg.
EXAMPLE 5 Production of a 100 mg. tablet
Torasemide of modificatio I is mixed with lactose monohydrate, maize starch and a part of the magnesium stearate. The mixture is compacted and sieved to the desired gain size and grain size distribution (granulate 1). Highly dispersed silicon dioxide and magnesium stearate are mixed and sieved and admixed with granulate 1. The mixture is then tableted in conventional manner:
Production formulation for 100,000 tablets:
torasemide: 10.0 kg.
lactose monohydrate: 2.0 kg.
maize starch: 7.7 kg.
silicon dioxide, highly dispersed: 0.2 kg.
magnesium stearate: 0.1 kg.
It will be understood that the specification and examples are illustrative but not limitative of the present invention and that other embodiments within the spirit and scope of the invention will suggest themselves to those skilled in the art.

Claims (6)

What is claimed is:
1. A process for the preparation of torasemide in the pure modification I (monoclinic, space group P2/c, .[.metling point 162° C.).]. .Iadd.in prism form) .Iaddend.from torasemide of modification II (monoclinic, space group P2/n, .[.melting point 169° C.).]. .Iadd.in leaflet form) .Iaddend.comprising stirring a suspension of torasemide of modification II in water with at least a catalytic amount of modification I, to rearrange the torasemide in modification II into .Iadd.stable .Iaddend.torasemide of modification I.
2. The process of claim 1, wherein the rearrangement is carried out at a temperature of from ambient temperature to 90° C. and the rearrangement is carried out for a time of from 3 hours to 14 days.
3. The process of claim 2, wherein the torasemide of modification II is used in the form of a salt-containing, approximately neutral solution, obtained by the precipitation of torasemide from alkaline solution.
4. The process of claim 2, wherein crystalline torasemide of modification I is recovered from the rearrangement reaction mixture.
5. The process of claim 1, wherein crystalline torasemide of modification I is recovered from the rearrangement reaction mixture.
6. The process of claim 1, wherein the torasemide of modification II is used in the form of a salt-containing, approximately neutral solution, obtained by the precipitation of torasemide from alkaline solution.
US07/985,053 1985-08-17 1992-12-03 Process for the preparation of a stable modification of torasemide Expired - Lifetime USRE34580E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/985,053 USRE34580E (en) 1985-08-17 1992-12-03 Process for the preparation of a stable modification of torasemide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19853529529 DE3529529A1 (en) 1985-08-17 1985-08-17 METHOD FOR PRODUCING A STABLE MODIFICATION OF TORASEMIDE
DE3529529 1985-08-17
US06/895,355 US4743693A (en) 1985-08-17 1986-08-11 Process for the preparation of a stable modification of torasemide
US07/985,053 USRE34580E (en) 1985-08-17 1992-12-03 Process for the preparation of a stable modification of torasemide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US06/895,355 Reissue US4743693A (en) 1985-08-17 1986-08-11 Process for the preparation of a stable modification of torasemide

Publications (1)

Publication Number Publication Date
USRE34580E true USRE34580E (en) 1994-04-05

Family

ID=6278766

Family Applications (4)

Application Number Title Priority Date Filing Date
US06/895,355 Ceased US4743693A (en) 1985-08-17 1986-08-11 Process for the preparation of a stable modification of torasemide
US07/111,439 Ceased US4822807A (en) 1985-08-17 1987-10-20 Pharmaceutical composition containing a stable modification of torasemide
US07/985,053 Expired - Lifetime USRE34580E (en) 1985-08-17 1992-12-03 Process for the preparation of a stable modification of torasemide
US08/043,631 Expired - Lifetime USRE34672E (en) 1985-08-17 1993-04-08 Pharmaceutical composition containing a stable modification of torasemide

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US06/895,355 Ceased US4743693A (en) 1985-08-17 1986-08-11 Process for the preparation of a stable modification of torasemide
US07/111,439 Ceased US4822807A (en) 1985-08-17 1987-10-20 Pharmaceutical composition containing a stable modification of torasemide

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/043,631 Expired - Lifetime USRE34672E (en) 1985-08-17 1993-04-08 Pharmaceutical composition containing a stable modification of torasemide

Country Status (25)

Country Link
US (4) US4743693A (en)
EP (1) EP0212537B1 (en)
JP (2) JPS6245576A (en)
KR (1) KR930009818B1 (en)
AU (1) AU573454B2 (en)
CA (1) CA1307277C (en)
CS (2) CS259891B2 (en)
DD (1) DD259858A5 (en)
DE (2) DE3529529A1 (en)
DK (1) DK162518C (en)
ES (1) ES2001522A6 (en)
FI (1) FI82189C (en)
GR (1) GR862139B (en)
HK (1) HK59994A (en)
HU (1) HU195778B (en)
IE (1) IE59237B1 (en)
IL (1) IL79672A (en)
LT (1) LT3596B (en)
NO (1) NO170079C (en)
NZ (1) NZ217172A (en)
PL (1) PL146086B1 (en)
PT (1) PT83186B (en)
SU (1) SU1480766A3 (en)
UA (1) UA7080A1 (en)
ZA (1) ZA866151B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914336A (en) 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US6399637B1 (en) * 1998-02-10 2002-06-04 Pliva, Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija, Dionicko Drustvo Crystal modification of torasemide
US6465496B1 (en) 1999-08-11 2002-10-15 Teva Pharmaceutical Industries, Ltd. Torsemide polymorphs
US6635765B2 (en) 2000-03-20 2003-10-21 Teva Pharmaceutical Industries, Ltd. Processes for preparing torsemide intermediate
US7002018B2 (en) 2001-08-03 2006-02-21 Ranbaxy Laboratories Limited Process for the preparation of amorphous form of torsemide
US20060100439A1 (en) * 2002-07-19 2006-05-11 Pliva Hrvatska D.O.O. Process for the preparation of modification I of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623620A1 (en) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh MOLDABLE, AQUEOUS, ALKALINE INJECTION SOLUTIONS FROM TORASEMID AND METHOD FOR THE PRODUCTION THEREOF
US5166162A (en) * 1990-03-02 1992-11-24 Adir Et Compagnie Pyridylsulfonylurea and pyridylsulfonylthiourea compounds
JP3586471B2 (en) * 1991-06-25 2004-11-10 三菱ウェルファーマ株式会社 Torasemide-containing pharmaceutical composition
US20030026835A1 (en) * 1999-02-15 2003-02-06 Sumitomo Pharmaceuticals Company Limited Tablets disintegrating rapidly in the oral cavity
DE1292303T1 (en) 2000-02-17 2003-09-18 Teva Pharma A STABLE PHARMACEUTICAL FORMULATION THAT CONTAINS TORSEMID MODIFICATION II
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
ITMI20020639A1 (en) * 2002-03-27 2003-09-29 Cosma S P A PHARMACEUTICAL COMPOSITIONS INCLUDING AS ACTIVE INGREDIENT 1-ISOPROPIL-3 ° (4-M-TOLUIDINO-3-PRIDIL) SULFONIL! -UREA
PT1465890E (en) * 2002-11-18 2007-05-31 Teva Pharma Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
US7678816B2 (en) * 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
ES2244324B1 (en) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. DIURETIC COMPOSITIONS OF PROLONGED RELEASE.
AT500576B1 (en) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag PROCESS FOR REPRESENTING CRYSTAL FORMS OF TORSEMID
US10178893B1 (en) * 2013-06-14 2019-01-15 Scott Bradley Baker Shoe
FR3018688A1 (en) * 2014-03-19 2015-09-25 Virbac USE OF LOW-DOSE TORASEMIDE IN A VETERINARY COMPOSITION
EP3031471A1 (en) 2014-12-12 2016-06-15 Ceva Sante Animale Veterinary composition for the treatment of pulmonary edema associated with heart failure in domestic animals
US12048677B2 (en) 2014-12-12 2024-07-30 Ceva Sante Animale Compositions and uses thereof for the treatment of heart failure in domestic animals
DK3173075T3 (en) * 2015-11-27 2019-01-21 Accupharma Spolka Z Ograniczona Odpowiedzialnoscia PHARMACEUTICAL COMBINATION PREPARATION OF ACE INHIBITOR AND LOOPDIURETIC
CN115417810B (en) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 Refining method of torsemide crystal form I

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2516025A1 (en) * 1974-04-17 1975-11-06 Christiaens Sa A NEW PYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30633A (en) * 1860-11-13 Improvement in fire-escapes
GB1593609A (en) * 1978-01-31 1981-07-22 Christiaens Sa A Pyridine sulfonamides
LU85193A1 (en) * 1984-01-31 1985-09-12 Christiaens Sa A NOVEL 4-PHENYLAMINOPYRIDINE DERIVATIVES, THEIR USE AND THEIR PREPARATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2516025A1 (en) * 1974-04-17 1975-11-06 Christiaens Sa A NEW PYRIDINE DERIVATIVES, THEIR PRODUCTION AND USE
US4018929A (en) * 1974-04-17 1977-04-19 A. Christiaens Societe Anonyme 3-Loweralkylcarbamylsulfonamido-4-phenylaminopyridine-N-oxides, derivatives thereof and pharmaceutical compositions containing same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Acta Cryst., (1978) pp. 2659 2662, 1304 1310. *
Acta Cryst., (1978) pp. 2659-2662, 1304-1310.
Condensed Chemical Dictionary, 10 Ed., p. 880 (1981). *
Morrison et al., Org. Chem., 3rd Ed., pp. 127 128 (1973). *
Morrison et al., Org. Chem., 3rd Ed., pp. 127-128 (1973).

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399637B1 (en) * 1998-02-10 2002-06-04 Pliva, Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija, Dionicko Drustvo Crystal modification of torasemide
US5914336A (en) 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US20040229919A1 (en) * 1998-10-02 2004-11-18 Pliva Hrvatska D.O.O. Crystal modification of torasemide
US6833379B2 (en) 1998-10-02 2004-12-21 Pliva Hrvatska D.O.O. Crystal modification of torasemide
US20060205951A1 (en) * 1998-10-02 2006-09-14 Pliva Hrvatska D.O.O. New crystal modification of torasemide
US6465496B1 (en) 1999-08-11 2002-10-15 Teva Pharmaceutical Industries, Ltd. Torsemide polymorphs
US6635765B2 (en) 2000-03-20 2003-10-21 Teva Pharmaceutical Industries, Ltd. Processes for preparing torsemide intermediate
US6670478B2 (en) 2000-03-20 2003-12-30 Teva Pharmaceutical Industries, Ltd. Process for preparing torsemide intermediate
US7002018B2 (en) 2001-08-03 2006-02-21 Ranbaxy Laboratories Limited Process for the preparation of amorphous form of torsemide
US20060100439A1 (en) * 2002-07-19 2006-05-11 Pliva Hrvatska D.O.O. Process for the preparation of modification I of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide

Also Published As

Publication number Publication date
CS594586A2 (en) 1988-03-15
NO170079C (en) 1992-09-09
UA7080A1 (en) 1995-06-30
DK385586A (en) 1987-02-18
NZ217172A (en) 1989-02-24
NO863305D0 (en) 1986-08-15
SU1480766A3 (en) 1989-05-15
KR930009818B1 (en) 1993-10-11
CS259891B2 (en) 1988-11-15
HK59994A (en) 1994-07-08
LTIP898A (en) 1995-03-27
DK385586D0 (en) 1986-08-13
DE3529529A1 (en) 1987-02-19
US4822807A (en) 1989-04-18
DE3529529C2 (en) 1987-05-27
LT3596B (en) 1995-12-27
JPH0415205B2 (en) 1992-03-17
US4743693A (en) 1988-05-10
NO170079B (en) 1992-06-01
AU573454B2 (en) 1988-06-09
PL261052A1 (en) 1987-11-02
IE862179L (en) 1987-02-17
HU195778B (en) 1988-07-28
FI82189C (en) 1991-02-11
DK162518B (en) 1991-11-11
AU6105586A (en) 1987-02-19
PT83186A (en) 1986-09-01
JPH02191255A (en) 1990-07-27
EP0212537A1 (en) 1987-03-04
CS419991A3 (en) 1992-06-17
PL146086B1 (en) 1988-12-31
GR862139B (en) 1986-12-30
ZA866151B (en) 1987-04-29
EP0212537B1 (en) 1990-01-03
DD259858A5 (en) 1988-09-07
IL79672A0 (en) 1986-11-30
FI863305A (en) 1987-02-18
ES2001522A6 (en) 1988-06-01
IE59237B1 (en) 1994-01-26
DK162518C (en) 1992-03-30
FI863305A0 (en) 1986-08-15
FI82189B (en) 1990-10-31
JPS6245576A (en) 1987-02-27
DE3667970D1 (en) 1990-02-08
JPH0643400B2 (en) 1994-06-08
NO863305L (en) 1987-02-18
HUT42069A (en) 1987-06-29
USRE34672E (en) 1994-07-26
CA1307277C (en) 1992-09-08
PT83186B (en) 1988-07-01
KR870002076A (en) 1987-03-30
IL79672A (en) 1990-01-18

Similar Documents

Publication Publication Date Title
USRE34580E (en) Process for the preparation of a stable modification of torasemide
US8344139B2 (en) Process for preparing crystalline polymorphic forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
US6888007B2 (en) Crystalline forms of EtO2C-Ch2-(R)Cgi-Aze-Pab-OH
US2446102A (en) Complex salts of streptomycin and process for preparing same
US2474758A (en) Complex salts of streptothricin
EP0611369B1 (en) Process for preparing (s) (+)-4,4'-(1-methyl-1,2-ethanediyl)-bis(2,6-piperazinedione)
US4902789A (en) Process and composition for the purification of amphotericin B
US6166045A (en) Torasemide of modification III
US2729642A (en) Water soluble salts of 8-(para-aminobenzyl) caffeine and method for their preparation
KR20040043171A (en) Novel modifications of the trometamol salt of R-thioctic acid and method for producing the same
US20080207896A1 (en) Process For the Manufacture of Mirtazapine
HRP940506A2 (en) Crystals of an antimicrobal compound
KR19980064287A (en) A New Form of Polysiloxane Mesylate (Type II)
JPS5885892A (en) Novel crystalline 3-cephem-4-carboxylate and purification
US4048158A (en) d-α-Isobutylsulfobenzylpenicillin hemi-solvate crystals
BG99161A (en) Method and intermediate product for oxytetracycline purification
CA1221367A (en) Fine crystalline isoxicam
US3287352A (en) Nu6-(2-hydroxyethyl) tubercidin and process therefor
KR20040081236A (en) Purification method of crystal form i of torasemide
Jackson A New Type of Sulfanilamide Derivative of D-Glucose. Sulfanilyl-2-amino-α-D-glucose and Certain Derivatives
US2960506A (en) New esters of reserpic acid alkyl esters
EP0827967A1 (en) Method for isolation and purification of S-(1,2-dicarboxyethyl) glutathione
JPS6072855A (en) Purification of s-carboxymethyl-l-cysteine
PL128735B1 (en) Method of obtaining erythromycin stearate of increased purity
JPH1095769A (en) Production of high-melting terfenadine

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: ROCHE DIAGNOSTICS GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BOEHRINGER MANNHEIM GMBH;REEL/FRAME:011122/0479

Effective date: 19990301

AS Assignment

Owner name: MEDA AB, SWEDEN

Free format text: CHANGE OF NAME;ASSIGNOR:ROCHE DIAGNOSTICS GMBH;REEL/FRAME:022678/0591

Effective date: 20090212